Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

When the Inflation Reduction Act was signed into law in 2022, it authorized a number of initiatives aimed at reducing the ...

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

Boehringer Ingelheim GmbH is open to more dealmaking to build its obesity portfolio even as it stays “laser-focused” on bringing its first weight-loss drug to market, its global head of therap ...

German drugmaker is vying for a place in the obesity market Company hopes liver data will help it carve out a niche Boehringer Ingelheim GmbH is open to more ... focused” on bringing its first ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's Breakthrough Therapy for the review of their experimental weight-loss drug for the ...